I-BEIJING SUCCEEDER TECHNOLOGY INC.

Uxwebhu lwesine olubalulekileyo lwesivumelwano, olukhokelwa yiKomiti yeThrombosis and Hemostasis ye-Chinese Association of Research Hospitals, lukhutshiwe.

"Imvumelwano yeengcali malunga nokubekwa kweliso kwiiklinikhi zeziyobisi ezifana neHeparin" yaphuhliswa ngokubambisana yiKomiti yeThrombosis and Hemostasis ye-Chinese Association of Research Hospitals kunye neSebe leSayensi yeLabhoratri ye-Chinese Geriatrics Society. Olu xwebhu, olubhalwe ngokubambisana ziingcali ezininzi ezivela kulo lonke elaseTshayina, luthathe iminyaka emibini ukuphuhliswa, emva kweengxoxo ezininzi kunye nohlaziyo. Uyilo lokugqibela ekugqibeleni lwavunyelwana ngalo lwaza lwapapashwa ngo-Agasti 2025 kwi-Chinese Journal of Laboratory Medicine, uMqulu 48, Issue 8.

Olu vumlwano lubonelela ngesikhokelo esisemgangathweni sokujonga amayeza afana ne-heparin elebhu, lubonelela ngenkxaso yelebhu ethembekileyo ngakumbi yokuphunyezwa ngokukhuselekileyo nangokusebenzayo konyango lwe-anticoagulant yeklinikhi. Ekugqibeleni, kuya kunceda uluhlu olubanzi lwezigulane kwaye kwenze unyango lwe-heparin anticoagulant lube yinto eqhelekileyo nechanekileyo.

ISISHWANKATHELO

Amayeza afana ne-heparin asetyenziswa rhoqo njenge-anticoagulants ukuthintela nokunyanga izifo ze-thromboembolic. Ukusetyenziswa ngokufanelekileyo kunye nokubeka esweni ngokufanelekileyo la mayeza kubalulekile ukuqinisekisa ukhuseleko kunye nokusebenza kakuhle konyango. Le mvumelwano yengcali isekelwe kwiincwadi ezifanelekileyo zasekhaya nezamazwe ngamazwe, iqwalasela ngokupheleleyo imeko yangoku kunye nenkqubela yokusetyenziswa kwe-heparin. Yabiza iphaneli yeengcali kwicandelo le-antithrombotic, kuquka iingcali zelebhu kunye nezeklinikhi, ukuze kuxoxwe ngezalathisi, idosi, kunye nokubeka esweni i-heparin. Ngokukodwa, icacise ukusetyenziswa kweklinikhi kwezalathisi zelebhu ezifana nomsebenzi we-anti-Xa kwaye yenze iingcebiso zeengcali ngenjongo yokukhuthaza ukusetyenziswa ngokukhuselekileyo nangokusebenzayo kwe-heparin kunye nokubeka esweni ilabhoratri kumgangatho ofanayo.Eli nqaku liphinde lashicilelwa kwakhona: I-Thrombosis kunye ne-Hemostasis (CSTH).

I-Beijing Succeeder Technology Inc. (ikhowudi yesitokhwe: 688338) ibisoloko ibandakanyeka kakhulu kwicandelo lokuxilongwa kwe-coagulation ukususela ekusekweni kwayo ngo-2003, kwaye izimisele ukuba yinkokeli kweli candelo. Ikomkhulu layo liseBeijing, le nkampani ineqela elinamandla le-R&D, lemveliso kunye nelokuthengisa, eligxile ekuveliseni izinto ezintsha kunye nokusetyenziswa kwetekhnoloji yokuxilonga i-thrombosis kunye ne-hemostasis.

Ngenxa yamandla ayo abalaseleyo obuchwephesha, iSucceeder iphumelele iipatenti ezingama-45 ezigunyazisiweyo, kuquka iipatenti zokuyila ezili-14, iipatenti zemodeli yokusetyenziswa ezili-16 kunye neepatenti zoyilo ezili-15. Le nkampani ikwanazo nezatifikethi zobhaliso lwemveliso yezixhobo zonyango zeKlasi yesiBini ezingama-32, izatifikethi zokufaka iifayile zeKlasi yoku-1 ezi-3, kunye nesatifikethi se-EU CE kwiimveliso ezili-14, kwaye iphumelele isatifikethi senkqubo yolawulo lomgangatho se-ISO 13485 ukuqinisekisa ukugqwesa kunye nokuzinza komgangatho wemveliso.

I-Succeeder ayisiyo nje kuphela ishishini eliphambili leBeijing Biomedicine Industry Leapfrog Development Project (G20), kodwa ikwaphumelele kwiBhodi yoBuchule beSayensi neTekhnoloji ngo-2020, ifezekisa uphuhliso oluphezulu lwenkampani. Okwangoku, inkampani yakhe inethiwekhi yokuthengisa kuzwelonke egubungela amakhulu eearhente kunye neeofisi. Iimveliso zayo zithengiswa kakuhle kwiindawo ezininzi zelizwe. Ikwakhulisa ngokukhutheleyo iimarike zaphesheya kwaye iphucula rhoqo ukhuphiswano lwayo lwamazwe ngamazwe.